Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates and working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Cancer biological therapy market industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Route of administration trends
2.1.4 Regional trends
Chapter 3 Cancer Biological Therapy Industry Insights
3.1 Industry landscape, 2018 - 2032
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of cancer worldwide
3.2.1.2 Growing geriatric population
3.2.1.3 Technological advancement in cancer biologics in developed countries
3.2.1.4 Increasing R&D funding coupled with favorable government policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Adverse effects of anti-cancer drug therapy
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By route of administration
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Pricing analysis
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company market share analysis, 2022
4.3 Company matrix analysis, 2022
4.4 Competitive positioning matrix
4.5 Strategy dashboard, 2021
Chapter 5 Cancer Biological Therapy Market, By Product
5.1 Key product trends
5.2 Monoclonal antibodies (MAB)
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.2 Naked MAB
5.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.3 Conjugated MAB
5.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.4 Bispecific MAB
5.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Vaccines
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.2 Preventive vaccines
5.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3 Therapeutic vaccines
5.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Cancer growth blockers
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4.2 Tyrosine kinase Inhibitors (TKI)
5.4.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4.3 Proteasome Inhibitors (PI)
5.4.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4.4 mTOR Inhibitors
5.4.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 Blood cell growth factors (BCGF)
5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5.2 Lenograstim
5.5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5.3 Filgrastim
5.5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6 Cytokines
5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6.2 Interferons
5.6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6.3 Interleukins
5.6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Cancer Biological Therapy Market, By Route of administration
6.1 Key route of administration trends
6.2 Oral
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Injectable
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Cancer Biological Therapy Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Poland
7.3.7 Switzerland
7.3.8 Netherlands
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Indonesia
7.4.7 Thailand
7.4.8 Vietnam
7.5 Latin America
7.5.1 Brazil
7.5.2 Argentina
7.5.3 Mexico
7.5.4 Chile
7.5.5 Columbia
7.5.6 Peru
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Egypt
7.6.5 Iran
Chapter 8 Company Profiles
8.1 AbbVie Inc.
8.2 Amgen Inc.
8.3 Astellas Pharma Inc.
8.4 AstraZeneca
8.5 Bayer AG
8.6 Bristol-Myers Squibb Company
8.7 Eisai Co., Ltd.
8.8 Eli Lilly and Company
8.9 F. Hoffmann-La Roche
8.10 GlaxoSmithKline plc
8.11 Incyte
8.12 Merck
8.13 Novartis
8.14 Otsuka
8.15 Pfizer
8.16 Sanofi
8.17 Seattle Genetics
8.18 Spectrum Pharmaceuticals
8.19 Takeda Pharmaceuticals
